Compugen (NASDAQ:CGEN - Get Free Report) issued its quarterly earnings data on Tuesday. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.07 by ($0.14), Zacks reports. The firm had revenue of $1.47 million for the quarter, compared to the consensus estimate of $17.47 million. Compugen had a return on equity of 2.62% and a net margin of 2.67%.
Compugen Price Performance
NASDAQ:CGEN traded down $0.01 during trading hours on Friday, reaching $1.66. 408,357 shares of the company were exchanged, compared to its average volume of 805,688. The business has a 50 day moving average of $2.05 and a 200 day moving average of $1.84. Compugen has a 1-year low of $1.35 and a 1-year high of $3.03. The company has a market capitalization of $148.13 million, a P/E ratio of 83.00 and a beta of 2.98.
Analysts Set New Price Targets
Several analysts recently issued reports on the company. StockNews.com downgraded Compugen from a "buy" rating to a "hold" rating in a research note on Wednesday. Oppenheimer began coverage on shares of Compugen in a research report on Monday, January 13th. They issued an "outperform" rating and a $4.00 target price for the company.
View Our Latest Research Report on CGEN
About Compugen
(
Get Free Report)
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.
Recommended Stories
Before you consider Compugen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compugen wasn't on the list.
While Compugen currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
